Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J/Centocor Files Golimumab In Three Indications

This article was originally published in The Pink Sheet Daily

Executive Summary

Company seeks approval in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

You may also be interested in...

Centocor Hits A Triple With Golimumab

Three Phase III trials prove TNF blocker works in RA – even after others in the class failed.

Anti-TNFs’ Link To Cancer In Children Under Investigation By FDA

Agency is investigating approximately 30 reports of cancer in pediatric patients.

UCB Seeks FDA Approval For Cimzia In Rheumatoid Arthritis

The biologic, which has yet to obtain a Crohn’s indication in the U.S. and Europe, is backed by efficacy data from three Phase III trials in RA.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts